Bevacizumab plus erlotinib combination for advanced HLRCC

A recent study, published in Cancer Research and Treatment in March 2019, provides the first real-world evidence of the promising treatment of advanced hereditary leiomyomatosis and renal cell carcinoma (HLRCC), a rare genetic syndrome resulting from mutations in the gene that makes an enzyme called fumarate hydratase. Ten patients with advanced HLRCC-associated renal cell carcinoma […]

read more

Treatment for hereditary leiomyomatosis renal cell carcinoma (HLRCC): a rare and aggressive form of kidney cancer

In this video, Dr W. Marston Linehan, chief of the Urologic Oncology Branch of the National Cancer Institute in America, discusses the treatment of hereditary leiomyomatosis and renal cell carcinoma (HLRCC). HLRCC is very rare inherited condition, in which patients are at risk of developing┬ánon-cancerous (benign) tumours in the muscle under the skin (cutaneous leiomyomas), […]

read more
Showing all 2 results
  TOP